Oxford Immunotec Global (NASDAQ:OXFD) is scheduled to be posting its quarterly earnings results before the market opens on Friday, November 9th. Analysts expect Oxford Immunotec Global to post earnings of ($0.10) per share for the quarter.
OXFD traded up $0.22 on Wednesday, reaching $15.47. 914 shares of the stock were exchanged, compared to its average volume of 152,247. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $19.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.86 and a current ratio of 5.39. The stock has a market cap of $411.33 million, a P/E ratio of -11.41 and a beta of -0.09.
A number of analysts have commented on the company. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Thursday, October 18th. ValuEngine raised Oxford Immunotec Global from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. Finally, Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, August 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $16.67.
In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $15.50, for a total transaction of $46,500.00. Following the completion of the transaction, the director now owns 9,000 shares in the company, valued at approximately $139,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Wrighton-Smith sold 86,100 shares of Oxford Immunotec Global stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $18.42, for a total value of $1,585,962.00. Following the transaction, the chief executive officer now owns 539,569 shares of the company’s stock, valued at approximately $9,938,860.98. The disclosure for this sale can be found here. Insiders have sold a total of 149,100 shares of company stock valued at $2,564,662 in the last quarter. Company insiders own 6.61% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/07/oxford-immunotec-global-oxfd-to-release-earnings-on-friday.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Story: Diversification
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.